首頁 > 市場調查報告書 > 製藥

HER2抑制劑市場規模、佔有率和成長分析（按藥物類型、用途、給藥途徑和地區分類）－產業預測，2026-2033年

市場調查報告書

商品編碼

1898345

HER2抑制劑市場規模、佔有率和成長分析（按藥物類型、用途、給藥途徑和地區分類）－產業預測，2026-2033年

HER2 Inhibitors Market Size, Share, and Growth Analysis, By Drug Type (Monoclonal Antibodies, Tyrosine Kinase Inhibitors), By Application (Breast Cancer, Gastric Cancer), By Route of Administration, By Region -Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 195 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球 HER2 抑制劑市場規模預計在 2024 年達到 101.4 億美元，從 2025 年的 111.7 億美元成長到 2033 年的 243 億美元，在預測期（2026-2033 年）內複合年成長率為 10.2%。

乳癌和胃癌，尤其是HER2陽性亞型的發生率不斷上升，顯著增加了對HER2抑制劑的需求，而HER2抑制劑是標靶癌症治療的關鍵組成部分。這些侵襲性癌症與較低的存活率有關，推動了精準醫療的發展，以改善患者的預後。免疫組織化學和螢光雜合反應等診斷方法的進步提高了早期檢測能力，並擴大了HER2抑制劑的應用範圍。此外，創新抗體藥物複合體（ADC）和生物類似藥的引入降低了成本，並提高了全球範圍內獲得這些重要治療的可及性。主要衛生監管機構的支持也進一步加速了HER2標靶治療的臨床開發，這些療法已成為癌症治療組合的核心部分，推動了市場成長，並支持HER2療法的持續創新。

全球HER2抑制劑市場促進因素

HER2陽性癌症（尤其是乳癌和胃癌）發生率的不斷上升是HER2抑制劑市場的主要促進因素。公眾意識的提高、教育的普及以及診斷技術的進步，使得更多病例能夠在早期被發現，從而擴大了需要HER2標靶治療的患者群體。這種不斷成長的需求迫使醫療系統改善服務以滿足患者的需求，進而推動了全球HER2抑制劑市場的擴張。因此，更高的檢出率和不斷成長的患者群體共同推動了該領域的持續成長。

全球HER2抑制劑市場受到抑制

全球HER2抑制劑市場面臨嚴峻挑戰，這些療法的高昂費用造成了許多不便，尤其是在中低收入國家。醫療系統和患者都承受著沉重的經濟負擔，這限制了這些關鍵治療方法的應用，阻礙了先進癌症治療的廣泛普及和公平獲取。這種經濟限制不僅阻礙了市場成長，也加劇了治療選擇上的不平等，最終影響患者的治療效果以及腫瘤治療進展在各地區的整體成效。因此，解決這些與成本相關的限制因素對於提高這些重要藥物的可近性至關重要。

全球HER2抑制劑市場趨勢

受標靶治療和個人化醫療創新推動，全球HER2抑制劑市場正經歷顯著成長。新型HER2抑制劑的研發，憑藉其更高的特異性和效力，正在改善HER2陽性癌症患者的治療效果。這種個人化治療方案不僅能提升臨床療效，還能最大限度地減少副作用，提高治療耐受性。隨著醫療機構不斷推動精準醫療，對這些先進抑制劑的需求預計將持續成長，這反映了癌症治療中個人化治療方法日益重視療效和安全性的趨勢。

Genentech（USA）
Hoffmann-La Roche（Switzerland）
Pfizer Inc.（USA）
AstraZeneca（United Kingdom）
Novartis AG（Switzerland）
Amgen Inc.（USA）
Eli Lilly and Company（USA）
Biogen Inc.（USA）
Sanofi SA（France）
Symbio Pharmaceuticals（USA）
Puma Biotechnology（USA）
Ipca Laboratories（India）

結論與建議

簡介目錄

Product Code: SQMIG35I2392

Global HER2 Inhibitors Market size was valued at USD 10.14 Billion in 2024 and is poised to grow from USD 11.17 Billion in 2025 to USD 24.3 Billion by 2033, growing at a CAGR of 10.2% during the forecast period (2026-2033).

The escalating prevalence of breast and gastric cancers, particularly HER2-positive variants, has significantly heightened the demand for HER2 inhibitors, crucial in targeted oncology therapies. These aggressive cancers are associated with lower survival rates, propelling a shift towards precision treatments aimed at improving patient outcomes. Advances in diagnostic methods, such as immunohistochemistry and fluorescence in situ hybridization, are enhancing early detection capabilities and broadening the application of HER2 inhibitors. Additionally, the introduction of innovative antibody-drug conjugates and biosimilars is driving down costs, thereby improving global access to vital care. Regulatory support from key health authorities is further accelerating the clinical development of HER2-targeted therapies, making them central to oncology portfolios, fostering market growth, and spurring ongoing innovation in HER2 treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global HER2 Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global HER2 Inhibitors Market Segments Analysis

Global HER2 Inhibitors Market is segmented by Treatment, Application, End User and region. Based on Treatment, the market is segmented into Monotherapy and Combination Therapy. Based on Application, the market is segmented into Squamous Cell Carcinoma, Adenocarcinoma, Large Cell Carcinoma, Breast Cancer and Other Applications. Based on End User, the market is segmented into Hospitals, Clinics and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global HER2 Inhibitors Market

The increasing incidence of HER2-positive cancers, particularly in breast and gastric forms, serves as a significant catalyst for the HER2 inhibitors market. Enhanced awareness, education, and advancements in diagnostic technologies are leading to more cases being identified at earlier stages, resulting in a larger patient cohort requiring HER2-targeted therapies. This rising demand is driving the expansion of the global HER2 inhibitors market, as healthcare systems are compelled to upgrade their offerings to meet the needs of these patients. Consequently, the combination of higher detection rates and an expanding patient population is fueling the ongoing growth in this sector.

Restraints in the Global HER2 Inhibitors Market

The global HER2 inhibitors market faces significant challenges due to the high costs associated with these treatments, which create barriers to access, especially in low- and middle-income countries. The financial burden imposed on healthcare systems and patients alike restricts the availability of these essential therapies, hindering broader adoption and equitable access to advanced cancer care. This economic limitation not only stifles market growth but also perpetuates disparities in treatment options, ultimately impacting patient outcomes and the overall effectiveness of oncology advancements across various regions. Addressing these cost-related constraints is crucial for enhancing accessibility to these vital medications.

Market Trends of the Global HER2 Inhibitors Market

The global HER2 inhibitors market is witnessing significant growth driven by innovations in targeted therapy and personalized medicine. The development of novel HER2 inhibitors with enhanced specificity and potency is enhancing treatment efficacy for patients with HER2-positive cancers. This tailored approach not only improves clinical outcomes but also minimizes adverse effects, making therapies more tolerable for patients. As healthcare providers continue to embrace precision medicine, the demand for these advanced inhibitors is expected to rise, reflecting a broader trend toward individualized treatment regimens in oncology that prioritize both efficacy and safety in cancer care.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Analysis
Technology Analysis
Case Studies
Customer Buying Behavior Analysis

Global HER2 Inhibitors Market Size by Treatment & CAGR (2026-2033)

Market Overview
Monotherapy
- Single-Agent HER2 Inhibitors
- Targeted HER2 Therapies
Combination Therapy
- HER2 Inhibitors Combined With Chemotherapy
- HER2 Inhibitors Combined With Targeted Therapies
- HER2 Inhibitors Combined With Hormonal Therapies

Global HER2 Inhibitors Market Size by Application & CAGR (2026-2033)

Market Overview
Squamous Cell Carcinoma
Adenocarcinoma
Large Cell Carcinoma
Breast Cancer
Other Applications

Global HER2 Inhibitors Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Clinics
Other End Users

Global HER2 Inhibitors Market Size & CAGR (2026-2033)

North America (Treatment, Application, End User)
- US
- Canada
Europe (Treatment, Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment, Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment, Application, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment, Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Genentech (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hoffmann-La Roche (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Symbio Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Puma Biotechnology (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipca Laboratories (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments